ArticleJournal of gastrointestinal oncology2024

Assessing the effectiveness and safety of surufatinib versus everolimus or sunitinib in advanced neuroendocrine neoplasms: insights from a real-world, retrospective cohort study using propensity score and inverse probability treatment weighting analysis.

Linhui Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.